Kwang Dong Pharmaceutical Co., Ltd. Stock

Equities

A009290

KR7009290008

Pharmaceuticals

End-of-day quote Korea S.E. 06:00:00 2024-05-13 pm EDT 5-day change 1st Jan Change
6,870 KRW +2.23% Intraday chart for Kwang Dong Pharmaceutical Co., Ltd. -0.15% -7.54%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2022 1,432B 1.05B Sales 2023 1,514B 1.11B Capitalization 298B 218M
Net income 2022 24.17B 17.7M Net income 2023 36.97B 27.06M EV / Sales 2022 0.12 x
Net cash position 2022 70.63B 51.7M Net Debt 2023 29.46B 21.56M EV / Sales 2023 0.22 x
P/E ratio 2022
10.1 x
P/E ratio 2023
8.14 x
Employees 1,024
Yield 2022
1.68%
Yield 2023
1.35%
Free-Float 58.04%
More Fundamentals * Assessed data
Dynamic Chart
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Distribute Eye Drop in Korea MT
Bioleaders Corporation announced that it has received KRW 2 billion in funding from Kwang Dong Pharmaceutical Co., Ltd. CI
Bioleaders Corporation announced that it expects to receive KRW 2 billion in funding from Kwang Dong Pharmaceutical Co., Ltd. CI
Kwang Dong Pharmaceutical Co., Ltd. agreed to acquire a 58.73% stake in BL Healthcare Corp. from BL Healthcare Corp. for KRW 30 billion CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Tranche Update on Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on April 11, 2023. CI
Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback announced on April 11, 2023, has closed with 1,000,000 shares, representing 2.43% for KRW 6,228.66 million. CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Kwang Dong Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,000,000 shares. CI
Kwang Dong Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Commercialize Myopia Drug in South Korea MT
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
More news
1 day+2.23%
1 week-0.15%
Current month+0.59%
1 month-1.29%
3 months-10.66%
6 months-1.86%
Current year-7.54%
More quotes
1 week
6 690.00
Extreme 6690
6 930.00
1 month
6 510.00
Extreme 6510
6 940.00
Current year
6 510.00
Extreme 6510
8 500.00
1 year
5 770.00
Extreme 5770
8 500.00
3 years
5 370.00
Extreme 5370
9 900.00
5 years
3 910.00
Extreme 3910
13 350.00
10 years
3 910.00
Extreme 3910
19 100.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 -
Director/Board Member 52 -
Director/Board Member 61 -
Members of the board TitleAgeSince
Chief Executive Officer 54 -
Director/Board Member 50 20-03-19
Director/Board Member 61 -
More insiders
Date Price Change Volume
24-05-13 6,870 +2.23% 125 881
24-05-13 6,720 -0.88% 86,384
24-05-10 6,780 -0.29% 65,881
24-05-09 6,800 -0.73% 59,624
24-05-08 6,850 0.00% 75,141

End-of-day quote Korea S.E., May 13, 2024

More quotes
Kwangdong Pharmaceutical Co Ltd is a Korea-based company principally engaged in the manufacturing and distribution of pharmaceuticals. The Company operates its business through five segments. The Mineral Water Business segment supplies drinking spring water under Samdasoo brand. The Distribution Business segment distributes health drinks under brand names of Vita500 and Corn Silk Tea. The Pharmacy Business segment provides Chinese prescription cold medicines, hypertension medicines, cerebral apoplexy medicines and health drinks. The Hospital Business segment offers anticancer agents, blood vessel adjuvants, vitamin D injections and others. The Other segment provides products which not covered by Pharmacy, Hospital and Distribution segments.
More about the company
  1. Stock Market
  2. Equities
  3. A009290 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW